-EN備份-SNA03
Indication
Cancers
Product Advantages
1.Low price
2.Low immunogenicity
3.Short half-life
4.Easy to be modified
5.Multi-aptamer drug can avoid the rising cost of synthesis and immunotoxicity caused by PEG derivatives, and also increase the efficacy of aptamer drug.
2.Low immunogenicity
3.Short half-life
4.Easy to be modified
5.Multi-aptamer drug can avoid the rising cost of synthesis and immunotoxicity caused by PEG derivatives, and also increase the efficacy of aptamer drug.
Status
Pre-clinical stage
Mechanism
Inhibition of LAG-3 allows T cells to regain cytotoxicity, thereby enhancing the anti-tumor effects.
Potential Market
Currently, there are no LAG-3 drugs on the market.
- LAG-3 (lymphocyte activation gene-3) is a member of the immune checkpoint proteins and is mainly expressed on regulatory T cells (Treg), activated T cells and natural killer cells (NK cell). When LAG-3 binds to a MHC class II molecule on antigen-presenting cell (APC), the activated T cells are down-regulated, thereby suppressing the immune response.
- Pre-clinical studies have shown that inhibition of LAG-3 allows T cells to regain cytotoxicity and enhance the efficacy for tumor killing. In addition, it can also reduce the function of regulatory T cells to suppress the immune system, so LAG-3 is considered to be more potential as a drug target than other immune checkpoint proteins. The LAG-3 aptamer, a patented product developed by our company, is composed of DNA that can specifically bind to the LAG-3 on T cells, subsequently activating T cells and prolonging the lifespan of T cells.
- SNA03 is a multi-aptamer drug constructed by our patented LAG-3 aptamer. It has a stronger binding affinity than the monomer form of LAG-3 aptamer and activates T cells more efficiently by blocking the binding of LAG-3 to MHC II molecules, then activating the immune response to inhibit tumor growth. Animal study results show that the response rate of SNA03 combined with PD-L1 antibody has increased from 20-30% (PD-L1 only) to over 90%, effectively overcoming the drawback of low response rate in the current immune checkpoint drugs. SNA03 is expected to proceed into scale-up process and drug toxicology evaluations in 2018, and apply for investigational new drug (IND) in 2019.
